DOP2021000103A - Pirazoles como moduladores de hemoglobina - Google Patents

Pirazoles como moduladores de hemoglobina

Info

Publication number
DOP2021000103A
DOP2021000103A DO2021000103A DO2021000103A DOP2021000103A DO P2021000103 A DOP2021000103 A DO P2021000103A DO 2021000103 A DO2021000103 A DO 2021000103A DO 2021000103 A DO2021000103 A DO 2021000103A DO P2021000103 A DOP2021000103 A DO P2021000103A
Authority
DO
Dominican Republic
Prior art keywords
modulators
pirazoles
tautomers
processes
relates
Prior art date
Application number
DO2021000103A
Other languages
English (en)
Inventor
Lee Dow Robert
Richard Roberts Lee
Walter Piotrowski David
Gopalsamy Ariamala
Venkat Narayanan Arjun
Casimiro-Garcia Agustin
Choi Chulho
Hepworth David
Gizem Yayla Hatice
Jasti Jayasankar
Howard Jones Lyn
Dineshkumar Parikh Mihir
Omezia Fadeyi Olugbeminiyi
Pelton Robinson Ralph Jr
Cabral Shawn
Zhu Chen Ming
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of DOP2021000103A publication Critical patent/DOP2021000103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con derivados de pirazol, con su uso en medicina, con composiciones que los contienen, con procesos para su preparación y con intermediarios utilizados en tales procesos. Más particularmente la invención se relaciona con moduladores de HbS de la Fórmula (I) (I) o tautómeros de los mismos, o sales farmacéuticamente aceptables de los moduladores o tautómeros de los mismos, en donde X, Y, R2 y R3 son como se definen en la descripción. Los moduladores de HbS son potencialmente útiles en el tratamiento de un amplio margen de trastornos, que incluyen enfermedad de células falciformes (SCD).
DO2021000103A 2018-11-29 2021-05-26 Pirazoles como moduladores de hemoglobina DOP2021000103A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862772815P 2018-11-29 2018-11-29
US201962915784P 2019-10-16 2019-10-16
PCT/IB2019/060171 WO2020109994A1 (en) 2018-11-29 2019-11-26 Pyrazoles as modulators of hemoglobin

Publications (1)

Publication Number Publication Date
DOP2021000103A true DOP2021000103A (es) 2021-07-30

Family

ID=68807213

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000103A DOP2021000103A (es) 2018-11-29 2021-05-26 Pirazoles como moduladores de hemoglobina

Country Status (22)

Country Link
US (3) US11014908B2 (es)
EP (1) EP3886984A1 (es)
JP (1) JP2022510628A (es)
KR (1) KR20210097161A (es)
CN (1) CN113329789A (es)
AU (1) AU2019387290A1 (es)
BR (1) BR112021009057A2 (es)
CA (1) CA3121139A1 (es)
CO (1) CO2021006924A2 (es)
CR (1) CR20210284A (es)
CU (1) CU20210044A7 (es)
DO (1) DOP2021000103A (es)
EC (1) ECSP21037191A (es)
IL (1) IL283408A (es)
MA (1) MA54283A (es)
MX (1) MX2021006095A (es)
PE (1) PE20211592A1 (es)
PH (1) PH12021551035A1 (es)
SG (1) SG11202104585YA (es)
TW (2) TWI736037B (es)
UY (1) UY38488A (es)
WO (1) WO2020109994A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20210044A7 (es) * 2018-11-29 2022-01-13 Pfizer Pirazoles como moduladores de hemoglobina
PE20221902A1 (es) 2020-01-24 2022-12-21 Pfizer Anticuerpos anti-e-selectina, composiciones y metodos de uso
CN112079774A (zh) * 2020-10-17 2020-12-15 甘肃天后光学科技有限公司 软性隐形眼镜用蓝光吸收剂、其制备方法及应用方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US8039674B2 (en) 2004-06-23 2011-10-18 Ono Pharmaceutical Co., Ltd. Compound having S1P receptor binding potency and use thereof
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
JP2007176799A (ja) 2005-12-27 2007-07-12 Sankyo Co Ltd 置換ベンゼン化合物を含有する医薬
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2011015524A2 (en) 2009-08-03 2011-02-10 Bayer Cropscience Ag Fungicide heterocycles derivatives
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
JP2013525476A (ja) * 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
AR082985A1 (es) 2010-09-14 2013-01-23 Exelixis Inc INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
ES2811129T3 (es) * 2011-12-28 2021-03-10 Global Blood Therapeutics Inc Compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2864707T3 (es) 2013-03-15 2021-10-14 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
JP6401772B2 (ja) 2013-03-15 2018-10-10 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
EA034922B1 (ru) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US20140271591A1 (en) * 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
KR101971385B1 (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9248199B2 (en) * 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
EP3157904B1 (en) 2014-06-20 2020-11-18 Institut Pasteur Korea Anti-infective compounds
WO2016043849A2 (en) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
JP6554547B2 (ja) 2014-11-03 2019-07-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂａｃｅ１阻害剤
HRP20230271T1 (hr) 2014-11-16 2023-06-09 Array Biopharma, Inc. Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogen sulfata
SG11201804647TA (en) 2015-12-04 2018-06-28 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3472150A1 (en) 2016-06-17 2019-04-24 Fronthera U.S. Pharmaceuticals LLC Hemoglobin modifier compounds and uses thereof
US11001559B2 (en) 2016-08-15 2021-05-11 Purdue Research Foundation 4-substituted aminoisoquinoline derivatives
CU20210044A7 (es) * 2018-11-29 2022-01-13 Pfizer Pirazoles como moduladores de hemoglobina

Also Published As

Publication number Publication date
SG11202104585YA (en) 2021-06-29
TW202033513A (zh) 2020-09-16
WO2020109994A1 (en) 2020-06-04
AU2019387290A1 (en) 2021-05-27
CR20210284A (es) 2021-07-09
TW202140452A (zh) 2021-11-01
CO2021006924A2 (es) 2021-06-10
US20200172512A1 (en) 2020-06-04
EP3886984A1 (en) 2021-10-06
CA3121139A1 (en) 2020-06-04
MA54283A (fr) 2022-03-09
US11702405B2 (en) 2023-07-18
PH12021551035A1 (en) 2021-12-06
TWI736037B (zh) 2021-08-11
CU20210044A7 (es) 2022-01-13
KR20210097161A (ko) 2021-08-06
US20220348555A1 (en) 2022-11-03
BR112021009057A2 (pt) 2021-08-10
US11014908B2 (en) 2021-05-25
JP2022510628A (ja) 2022-01-27
ECSP21037191A (es) 2021-06-30
IL283408A (en) 2021-07-29
CN113329789A (zh) 2021-08-31
UY38488A (es) 2020-06-30
PE20211592A1 (es) 2021-08-18
US20230382892A1 (en) 2023-11-30
MX2021006095A (es) 2021-07-06

Similar Documents

Publication Publication Date Title
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
DOP2021000103A (es) Pirazoles como moduladores de hemoglobina
DOP2021000019A (es) Inhibidores de inflamasoma nlrp3
NI201400031A (es) Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
UY35275A (es) Derivados de aminopirazina
CO7160077A2 (es) Compuestos de pirazol sustituidos como antagonistas de lpar
CO2022004723A2 (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
CO2022004698A2 (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
DOP2015000214A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CO2023000056A2 (es) Derivados de amidopirimidona
CO2022008313A2 (es) Compuestos químicos
CL2019002601A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos.
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
CO2021004553A2 (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP055673A (es) Derivados de 4-(3,5-dicianofenoxi) pirazol para el uso como moduladores de transcriptasa reversa en el tratamiento del vih
ECSP18056196A (es) Derivados de indano
UY31812A (es) Derivados de cinolina como inhibidores de csf-1
UY30699A1 (es) Derivados sustituidos de 4-fenilamino-quinolina-3-carboxamidas, sales farmacéuticamente aceptables, procesos de preparacion, composiciones conteniéndolos y aplicaciones